Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR).
   Google Scholar   
Citation:
J. Clin. Oncol. vol 29 (15s) abstr 2019
Year:
2011
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
Yes
DataSharing:
No
Parents:
None
Children:
1040  
Program:
OGC
Primary Committee:
Neuro-Onc
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                     
Primary Study
NCCTG-N0776
Secondary Studies:
Phases:
2
Keywords: